Flore Inc

What Flore Inc does

Flore Inc is a US-based precision gut health company that operates a Test-to-Treat model for personalized probiotics. Founded in 2018 (originally as Sun Genomics) and headquartered in Joliet, Illinois, the company sequences customer stool samples using shotgun metagenomics (Kraken2) at independent CLIA/CAP-accredited laboratories, then matches each profile against 352 markers, 23,000+ microbial species, and a proprietary outcomes database of 40,000+ historical formulations. A strain-selection algorithm draws from a library of 68 probiotic strains and 40+ prebiotics to manufacture a custom 5–7 strain synbiotic in-house in Joliet, with reformulation available on retest. The company reports 23,447 sequenced microbiomes, 18,392+ customers served, a 95.1% complaint-free rate, and a 4.4 TrustScore on 318 verified Trustpilot reviews as of 2026.

The commercial model blends direct-to-consumer e-commerce (flore.com, portal.flore.com) with a B2B clinical channel (Flore Clinical at floreclinical.com) that lets licensed providers prescribe personalized formulas and set patient markups. GoodOnes, a wholly owned sub-brand launched in September 2024, extends the company into off-the-shelf targeted OTC probiotics priced from $49, while the Autism Probiotics sub-brand and the ASD-specific formulation pathway are supported by a 2024 peer-reviewed pilot study co-published with Arizona State University's Britton Lab in mSystems (DOI: 10.1128/msystems.00503-24). Revenue derives from 3-, 6-, and 12-month personalized subscription programs (priced $89–$109.75/month or $297–$1,068 paid in full), GoodOnes unit sales, $99 microbiome coaching add-ons with Dr. Marina De León, PhD, and provider-driven Flore Clinical orders. Distribution is overwhelmingly DTC within the United States, augmented by a 2024 channel partnership with Evexia Diagnostics that opens access to a 20,000-clinician network.

Flore's moat attempts rest on the proprietary formulation data flywheel, in-house custom manufacturing, published clinical evidence, and a clinical-grade compliance posture (HIPAA, GDPR, CCPA, SOC 2 Type II, PCI-DSS). Following the 2023 acquisition of Sun Genomics and a strategic partnership with DSM (now DSM-Firmenich), the company has consolidated sequencing IP, scaled product breadth, and added a 2024 mSystems publication as the only peer-reviewed validation in the precision synbiotic category. Strategic risks include dependence on third-party CLIA/CAP labs for sequencing, reliance on external OpenAI models for the AI Report Analyzer feature, a small leadership team of fewer than 10 employees, no publicly disclosed revenue, and only $8.65 million in disclosed institutional funding (Series A in 2020 as Sun Genomics).

Name

Flore Inc

Legal name

Sun Genomics, Inc.

Website

https://flore.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Flore Inc is a US precision gut health company that sequences customer microbiomes and manufactures personalized probiotic formulas, serving DTC consumers, licensed clinicians via Flore Clinical, and the OTC market through the GoodOnes sub-brand.

Ownership category

akta.pro rank

Product category

Personalized Microbiome Probiotics

NAICS

Food (Health) Supplement Retailers (456191), Pharmaceutical Preparation Manufacturing (325412)

akta.pro primary industry

Probiotics & Digestive Health Supplements (CRADAGAF)

akta.pro secondary industries

Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ), Probiotics (Human & Animal Strains, Spore-Formers, Synbiotic Bases) (AFAJAJAE), Probiotic, Prebiotic & Gut-Health Foods Manufacturing (Fermented Functional Foods, Synbiotics) (AFAKAJAH)

Keywords

• Personalized probiotics
• Microbiome testing
• Gut-brain synbiotics
• Precision nutraceuticals
• Clinical provider platform

Headquarters

HQ city

Joliet

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Personalized Probiotic Subscriptions and One-Time Purchases: Flore's primary revenue stream is the sale of personalized probiotic formulas, sold as subscription programs (monthly payments across a defined term: 3, 6, or 12 months) or as one-time full payments. Programs include the core personalized formula (5-7 targeted strains from a library of 68 strains plus 40+ prebiotics), with optional add-ons such as gut health coaching ($99) and mid-cycle reformulation ($175).
2. GoodOnes™ Targeted Probiotics (OTC): GoodOnes is a line of over-the-counter, single-strain targeted probiotics sold directly to consumers at $49 per bottle (single), $90 for a 2-pack, or $179 for a 4-pack, with subscribe-and-save options. These are off-the-shelf targeted formulas (one job per bottle) powered by the same Flore Clinical formulary intelligence, requiring no microbiome test.
3. Flore Clinical Provider Platform: Healthcare providers (clinics, dietitians, researchers) use the Flore Clinical portal to order personalized probiotic formulas for their patients. Providers can set a markup percentage on patient orders, generating revenue through a spread/pricing markup model. Providers pay for patient formulations ordered through the platform.
4. Microbiome Coaching Sessions: 30-minute 1:1 microbiome coaching sessions with Dr. Marina De León, PhD (Microbiome Health & Nutrition Consultant) are sold as a $99 add-on to the personalized probiotic program. Sessions are available in 15, 30, 45, or 60-minute lengths through the portal.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels7 records

Core offering

Flore sequences customers' gut microbiomes via CLIA/CAP-accredited third-party labs using shotgun metagenomics, then manufactures a personalized synbiotic formula (typically 5–7 strains from a library of 68 probiotic strains and 40+ prebiotics) in-house in Joliet, IL and ships it as capsules or powder. Programs run for 3, 6, or 12 months; a separate OTC line (GoodOnes™) sells off-the-shelf single-strain targeted probiotics without a test. A provider-facing platform (Flore Clinical) lets licensed clinicians prescribe these formulas and apply markups, while a sub-brand (Autism Probiotics) addresses the ASD-specific pediatric pathway.

Product overview

Flore Inc operates as a precision gut health company with a Test-to-Treat model. The core product is Flore Personalized Probiotics — manufactured-to-spec formulas built from individual microbiome sequencing data using a library of 68 probiotic strains and 40+ prebiotics, matched against 40,000+ real formulation outcomes. The portfolio includes Flore Clinical (provider-facing platform for prescribing personalized probiotics), GoodOnes™ (targeted ready-made probiotics available without testing), and Autism Probiotics (dedicated formulations for neurodiverse individuals). Optional microbiome coaching sessions with Dr. Marina De León are available as add-ons. Products are delivered as capsules or powder (never liquid) with reformulation on retest. Manufacturing is performed in-house in Joliet, IL.

Differentiator

Problem solved

Functional benefit

Brands

• GoodOnes: Targeted, ready-made probiotics for specific gut goals (constipation, mood, immune, skin, metabolic, kids) - single-strain, one-job synbiotics starting at $49
• Flore Clinical
• Autism Probiotics

Products and services

• Flore Personalized Probiotics Test-to-Treat personalized synbiotic program: customer gut microbiome is sequenced (shotgun metagenomics, 352 markers, 23,000+ microbes) via CLIA/CAP labs and matched against 40,000+ real formulation outcomes to manufacture a custom 5–7 strain formula from a library of 68 probiotic strains and 40+ prebiotics. Sold as 3-, 6-, or 12-month supply subscriptions (capsules or powder) with optional gut-brain-axis psychobiotic targeting and mid-cycle reformulation.
• Flore Clinical Clinical-grade portal for licensed healthcare providers (MDs, DOs, NDs, DCs, NPs, PAs, RDs, CNS, LAc, PharmDs) to order personalized probiotic formulas for their patients, track microbiome changes over time, manage multiple patients from one HIPAA-compliant dashboard, and apply their own pricing markup to patient orders. Includes EHR-style records and Shopify/Stripe/LIMS integrations.
• GoodOnes™ Targeted Probiotics Over-the-counter, single-strain targeted probiotic line requiring no microbiome test; each bottle is "one job" (constipation, mood/stress, immune, skin, metabolic, kids, gentle gut, women's, muscle) built from the same Flore Clinical formulary intelligence. Sold at $49/single, $90/2-pack, $179/4-pack, with subscribe-and-save options.
• Autism Probiotics Dedicated probiotic line and formulation pathway for autistic adults and children, backed by a 2024 peer-reviewed pilot study in mSystems (ASM). Includes pediatric-specific options (The Little One, The Calm Little One) and an #ActuallyAutistic-aligned brand positioning.
• Microbiome Coaching with Dr. Marina De León Paid 1:1 microbiome health and nutrition coaching sessions (15, 30, 45, or 60 minutes) with Dr. Marina De León, PhD; priced at $99 per 30-minute session. Sold as an add-on to the Flore personalized program and bookable directly through the portal.

Quantifiable outcome

• 95.1% complaint-free rate across all Flore formulations
• +3 more outcomes

Named customers2 records

Segments6 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability4 records

Feature5 records

Partnerships

Seven partnerships are on record, tiered core, significant and supporting.

• Arizona State University — Britton LabcoreStrategic or Co-development Partner · 1 January 2024Flore partnered with Arizona State University's Britton Lab — one of the world's leading microbiome research programs — to co-publish a 2024 peer-reviewed pilot open-label study in mSystems demonstrating that Flore precision synbiotics increased gut microbiome diversity and improved GI symptoms in autism spectrum disorder. The study was conducted under IRB oversight (Protocol #2026-FLORE-001). ASU is also listed as a compatible lab source for customer microbiome test data upload.
• Evexia DiagnosticssignificantChannel Partner/ Reseller/ Distributor · 1 January 2024Flore Clinical partnered with Evexia Diagnostics to distribute personalized microbiome mapping technology to Evexia's network of 20,000 clinicians, expanding the reach of the Flore Clinical provider platform into a large network of healthcare providers. Coverage reported by KXAN Austin and NutraIngredients.
• CLIA/CAP-Accredited Sequencing LaboratoriescoreTechnology or IntegrationFlore uses independent accredited CLIA/CAP-certified laboratories (not Flore itself) to perform microbiome DNA sequencing on customer stool samples. This is described as a deliberate quality choice. Compatible labs include SunGenomics, ASU Britton Lab, and CosmosID — customers can upload results from any of these labs to drive their personalized formula.
• Shopify Inc.coreTechnology or IntegrationFlore's online store is hosted on Shopify's e-commerce platform, which handles checkout, payment processing, and order management. The privacy policy notes that customer data may also be shared with Shopify for the purpose of providing products and services.
• StripecoreTechnology or IntegrationStripe is the payment processing partner used by Flore Clinical's provider platform for patient checkout with dynamic pricing per session. The Flore portal includes Stripe integration settings for clinic administrators to configure webhook endpoints and API keys.
• CosmosIDsupportingTechnology or IntegrationCosmosID is one of the third-party microbiome sequencing labs whose test results are compatible with Flore's platform. Customers who have used CosmosID for gut microbiome testing can upload their results to Flore to generate a personalized probiotic formula without taking a new test.
• Sun Genomics (Acquired)coreStrategic or Co-development PartnerFlore acquired Sun Genomics, bringing years of microbiome sequencing experience and tens of thousands of real formulations behind every Flore formula. Sun Genomics was the original precision probiotic company, founded in 2018. All customer data and history from Sun Genomics carried over to Flore under the same privacy and security standards.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Others

• Evexia Diagnostics: Functional medicine diagnostic distributor and Flore Clinical's distribution partner. Listed because it controls access to 20,000 clinicians and shapes Flore Clinical's go-to-market surface area.

Direct peers

• DayTwo: Microbiome-based personalized nutrition platform originally focused on blood sugar / glycemic response, now expanding to gut health. A direct peer in the consumer microbiome personalization category.
• ZOE: Personalized nutrition company combining at-home gut microbiome testing with blood sugar and blood fat analysis to deliver personalized food scores. Competes with Flore in the test-driven personalized wellness category and is explicitly listed on Flore's comparison pages.
• Seed Health: Premium daily synbiotic brand with a direct-to-consumer subscription model and deep microbiome science branding. Competes with Flore for the same health-conscious consumer with a non-personalized, fixed-formula positioning.
• Viome: Direct competitor offering at-home microbiome testing plus personalized nutrition recommendations (including probiotics and supplements). Closest analog to Flore's test-to-treat model and explicitly named on Flore's comparison pages.
• BIOHM: Gut-health probiotic brand combining probiotics and digestive enzymes to address bacteria and fungi in the microbiome. Directly named on Flore's comparison pages and serves a similar digestive-health consumer.
• Pendulum: Clinically-studied probiotic company focused on metabolic health (including Akkermansia muciniphila and GLP-1 pathways). Competes with Flore on evidence-based, strain-specific probiotic positioning in the metabolic and gut-health segments.
• Ombre (LifeBiome): Personalized microbiome-based probiotic brand sold DTC. Competes head-to-head with Flore on test-to-personalized-formula positioning and is explicitly named on Flore's comparison pages.

Emerging players

• Thryve (now OmbreLife / consolidated): Microbiome testing and personalized probiotic company with a smaller consumer brand presence; comparable in technology stack (microbiome sequencing → personalized supplement) but with less brand scale than Flore.
• Atlas Biomed: DNA and microbiome test company offering personalized nutrition and probiotic recommendations. Comparable to Flore as a European-headquartered microbiome test-to-recommendation service competing for the same health-conscious consumer.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/flore
• YouTubeyoutube.com/@flore
• Facebookfacebook.com/flore
• LinkedInlinkedin.com/company/flore
• Instagraminstagram.com/flore

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Flore Inc